Report Information More information from: https ://www.wis eguyreports .com/reports /575869
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016 Report / Search Code: WGR575869
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 28 June, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016’, provides in depth analys is on P2X Purinoceptor 3 (P2RX3) targeted pipeline therapeutics . The report provides comprehens ive information on the P2X Purinoceptor 3 (P2RX3) , targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for P2X Purinoceptor 3 (P2RX3) - The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es P2X Purinoceptor 3 (P2RX3) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3) - Identify the us e of drugs for target identification and drug repurpos ing - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies
- Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding P2X Purinoceptor 3 (P2RX3) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 4 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 P2X Purinoceptor 3 (P2RX3) Overview 7 Therapeutics Development 8 P2X Purinoceptor 3 (P2RX3) - Products under Development by Stage of Development 8 P2X Purinoceptor 3 (P2RX3) - Products under Development by Therapy Area 9 P2X Purinoceptor 3 (P2RX3) - Products under Development by Indication 10 P2X Purinoceptor 3 (P2RX3) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 P2X Purinoceptor 3 (P2RX3) - Products under Development by Companies 13 P2X Purinoceptor 3 (P2RX3) - Products under Development by Univers ities /Ins titutes 15 P2X Purinoceptor 3 (P2RX3) - Therapeutics As s es s ment 17 As s es s ment by Monotherapy/Combination Products 17 As s es s ment by Mechanis m of Action 18 As s es s ment by Route of Adminis tration 19 As s es s ment by Molecule Type 20 P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development 22 Afferent Pharmaceuticals , Inc. 22 As ana BioSciences , LLC 23 Integral Molecular, Inc. 24 Neurim Pharmaceuticals Ltd 25 Pfizer Inc. 26 Shionogi & Co., Ltd. 27 P2X Purinoceptor 3 (P2RX3) - Drug Profiles 28 AF-130 - Drug Profile 28 Product Des cription 28 Mechanis m Of Action 28 R& D Progres s 28 AF-219 - Drug Profile 29 Product Des cription 29 Mechanis m Of Action 29 R& D Progres s 29 ASN-009 - Drug Profile 33 Product Des cription 33 Mechanis m Of Action 33 R& D Progres s 33 Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile 34 Product Des cription 34 Mechanis m Of Action 34 R& D Progres s 34 Monoclonal Antibody to Antagonize P2X2 and P2X3 for Vis ceral Pain - Drug Profile 35 Product Des cription 35 Mechanis m Of Action 35 R& D Progres s 35 NEO-5937 - Drug Profile 36 Product Des cription 36 Mechanis m Of Action 36 R& D Progres s 36 OSX-300 - Drug Profile 37 Product Des cription 37 Mechanis m Of Action 37 R& D Progres s 37 OSX-300 Backups - Drug Profile 38 Product Des cription 38 Mechanis m Of Action 38 R& D Progres s 38 piromelatine - Drug Profile 39 Product Des cription 39 Mechanis m Of Action 39 R& D Progres s 39 Small Molecule to Antagonize P2X3 Receptor for Hyperalges ia - Drug Profile 41 Product Des cription 41
Mechanis m Of Action 41 R& D Progres s 41 P2X Purinoceptor 3 (P2RX3) - Dormant Projects 42 P2X Purinoceptor 3 (P2RX3) - Dis continued Products 44 P2X Purinoceptor 3 (P2RX3) - Featured News & Pres s Releas es 45 May 18, 2016: Afferent Pharmaceuticals Reports Cardiovas cular Res earch Showing P2X3 Antagonis m Succes s fully Reduces Hypertens ion By Res toring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference 45 May 16, 2016: Afferent Pharmaceuticals Pres ents Updated Pos itive Res ults with AF219 from Phas e 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 46 Apr 25, 2016: Afferent Pharmaceuticals Announces Pres entation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference 48 Apr 25, 2016: Afferent Pharmaceuticals Announces Pres entation of Hypertens ion Res earch at the Upcoming American Thoracic Society 2016 International Conference 49 Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phas e 1 Clinical Trial 49 Nov 11, 2015: Afferent Pharmaceuticals Announces Phas e 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibros is (IPF) Patients 50 Sep 28, 2015: Afferent Pharmaceuticals Announces Pos itive Res ults in Phas e 2b Chronic Cough Trial 51 Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demons trate Improvements in Pain and Urinary Urgency in Inters titial Cys titis / Bladder Pain Syndrome 52 Nov 25, 2014: Afferent Clinical Data Demons trating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Publis hed In The Lancet 53 Sep 09, 2013: Afferent Pharmaceuticals Reports Pos itive Phas e 2 Clinical Data for the Company’s Lead P2X3 Antagonis t, AF-219 54 Feb 18, 2013: Neurim Pharma Announces Pos itive Phas e II Clinical Trial Res ults Of Piromelatine For Treatment Of Ins omnia 55 Jul 24, 2011: Neurim Announces Pos itive Res ults From Phas e I And Phas e Ib Clinical Trials With Neu-P11 56 Aug 25, 2010: Afferent Reports Data Supporting Potential Utility Of P2X3 Antagonis ts In Lowering Bladder Reflexes 57 Appendix 58 Methodology 58 Coverage 58 Secondary Res earch 58 Primary Res earch 58 Expert Panel Validation 58 Contact Us 58 Dis claimer 59 Lis t of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 Number of Products under Development by Companies , H1 2016 13 Products under Development by Companies , H1 2016 14 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 15 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 16 As s es s ment by Monotherapy/Combination Products , H1 2016 17 Number of Products by Stage and Mechanis m of Action, H1 2016 18 Number of Products by Stage and Route of Adminis tration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Afferent Pharmaceuticals , Inc., H1 2016 22 Pipeline by As ana BioSciences , LLC, H1 2016 23 Pipeline by Integral Molecular, Inc., H1 2016 24 Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 25 Pipeline by Pfizer Inc., H1 2016 26 Pipeline by Shionogi & Co., Ltd., H1 2016 27 Dormant Projects , H1 2016 42 Dormant Projects (Contd..1), H1 2016 43 Dis continued Products , H1 2016 44 Lis t of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analys is by Early Stage Products , H1 2016 12 As s es s ment by Monotherapy/Combination Products , H1 2016 17 Number of Products by Stage and Mechanis m of Actions , H1 2016 18 Number of Products by Stage and Routes of Adminis tration, H1 2016 19 Number of Products by Molecule Types , H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 20
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349